Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Flm2.8
Flmodafinil (CRL-40,940) – Forschung
Überwiegend Mechanismus / Beobachtung
5 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Flmodafinil (CRL-40,940) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1997–2026.
Basierend auf 5 Studien · 2 RCTs
Konfidenz
Geringe Konfidenz
Nach Outcome
Focus & attention (modafinil-class, unproven for flmodafinil)Ein Bisfluor-Analogon von Modafinil, das für Fokus/Aufmerksamkeit vermarktet wird; dies ist aus Modafinil extrapoliert und für Flmodafinil unbelegt, ohne direkte Wirksamkeitsdaten am Menschen. · Nicht etabliert (keine direkten Humandaten)
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Wakefulness & fatigueWachheit/Wachsamkeit in Analogie zur eugeroischen Modafinil-Klasse; für Flmodafinil unbelegt und mit Risiken für Schlaflosigkeit, Angst, erhöhten Blutdruck/Herzfrequenz sowie seltene schwere Hautreaktionen verbunden. · Nicht etabliert (keine direkten Humandaten)
Überwiegend Mechanismus / Beobachtung4 Studien
Cognition (modafinil parent evidence)
Zu wenige bewertete Studien2 Studien
Sleep disruption / insomnia
Zu wenige bewertete Studien2 Studien
Stetige Forschung
1 Studie in den letzten 5 Jahren
199720112026
1RCT2000
Einfach gesagt: Modafinil significantly improved the ability to stay awake compared with placebo ... The most common adverse events were headache, nausea, and nervousness. Modafinil was well tolerated and was not associated with any serious adverse events.
US Modafinil in Narcolepsy Multicenter Study Group. · Neurology (2000)
MODAFINIL (parent/analogue), NOT FLMODAFINIL: a large multicenter randomized placebo-controlled trial of modafinil for excessive daytime somnolence in narcolepsy — parent-drug human evidence
Modafinil improved objective wakefulness vs placebo; the most common adverse events were headache, nausea and nervousness — the same symptoms extrapolated to flmodafinil
Reinforces the modafinil-class effect AND its typical adverse-event profile in supervised humans, for the PARENT compound only
Einfach gesagt: Modafinil may well deserve the title of the first well-validated pharmaceutical nootropic agent ... modafinil appears to consistently engender enhancement of attention, executive functions, and learning. Importantly, we did not observe any preponderances for side effects or mood changes.
Battleday RM, Brem AK. · European Neuropsychopharmacology (2015)
MODAFINIL (parent/analogue), NOT FLMODAFINIL: a systematic review of modafinil for cognitive neuroenhancement in healthy non-sleep-deprived adults — included here to show what the RELATED drug does, not what flmodafinil does
Found modest, task-dependent benefits to attention, executive function and learning with modafinil, especially on more complex tasks
Cited by flmodafinil vendors as if it were flmodafinil evidence — it is NOT; flmodafinil is a different fluorinated analogue with no human cognition trials
Einfach gesagt: Compared with placebo, modafinil 200 and 400 mg significantly increased the mean sleep latency on the Maintenance of Wakefulness Test by 40% and 54% ... Modafinil produced no changes in blood pressure or heart rate ... As little as a 200-mg daily dose of modafinil is therefore an effective and well-tolerated treatment.
Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF. · Neurology (1997)
MODAFINIL (parent/analogue), NOT FLMODAFINIL: a randomized, double-blind, placebo-controlled crossover trial of modafinil for excessive daytime sleepiness in narcolepsy — real human evidence for the PARENT drug
Modafinil reduced objective and subjective daytime sleepiness vs placebo and was generally well tolerated in this supervised clinical population
Establishes the modafinil-class wakefulness effect in humans — but for modafinil, NOT for the unstudied analogue flmodafinil
Einfach gesagt: NLS-4 at 64 mg/kg induced significantly longer wakefulness duration than modafinil at 150 mg/kg ... Our results indicate that NLS-4 is a highly potent wake-promoting drug with no sign of hypersomnia rebound.
Luca G, Bandarabadi M, Konofal E, Lecendreux M, Ferrié L, Figadère B, Tafti M. · Frontiers in Neuroscience (2018)
FLMODAFINIL-SPECIFIC: the only direct in-vivo characterization of flmodafinil (here under its synonym lauflumide / NLS-4) — a mouse EEG/EMG study comparing it to modafinil and vehicle
Lauflumide 64 mg/kg intraperitoneally produced significantly LONGER wakefulness than modafinil 150 mg/kg, supporting the 'more potent than modafinil' framing — but in mice, not humans
Recovery sleep after lauflumide showed less NREM and less delta activity than modafinil, which the authors read as a lower need for recovery despite longer wakefulness
Einfach gesagt: Flmodafinil (CRL-40,940 ...) and fladrafinil (CRL-40,941 ...) are structural analogs of modafinil. Their reported stimulating effects on the central nervous system have contributed to an increasing popularity outside the medical field, particularly for the enhancement of cognitive performance.
Krug O, Guddat S, Görgens C, Walpurgis K, Toma F, Thomas A, Thevis M. · Drug Testing and Analysis (2026)
FLMODAFINIL-SPECIFIC (and the one direct HUMAN study): a doping-control study in which six volunteers ingested 20 mg of flmodafinil or its prodrug fladrafinil, characterizing how the drug is metabolized and eliminated to define anti-doping detection windows
Confirms flmodafinil is a structural analogue of modafinil used outside medicine as a cognitive/wakefulness 'research chemical' — documenting the grey-market use, not any clinical benefit
Notes that the prodrug fladrafinil converts to flmodafinil in the body, relevant to what a grey-market buyer actually metabolizes